
Susan Murphy, OT, ScD, explained how leveraging participatory research methods and positioning patients and community members as essential co-creators rather than passive recipients of medical interventions can lead to meaningful collective health solutions for complex medical challenges.
In the Monday lecture, Michael Brenner, MD, discussed new paradigms in the immunopathogenesis of rheumatoid arthritis and other autoimmune diseases that come from taking an “unbiased” approach.
Ali Guermazi, MD, PhD, MSc, was among the experts discussing how artificial intelligence (AI) is changing imaging for the diagnosis and management of rheumatic diseases.
Experts, including Jasvinder Singh, MD, MPH, examined the dynamics of gout and cardiometabolic comorbidity management. Gout is an independent risk factor for any vascular event, coronary heart disease, peripheral vascular disease, and atrial fibrillation, he explained.
Three experts, including David Pisetsky, MD, PhD, shared pearls of wisdom with ACR Convergence attendees to help them achieve greatness in their home practices. Each master clinician agreed that the art of close observation is essential in interactions with patients.
Discussing sex, sexuality, and intimacy can be daunting for patients and providers, but ignoring sexual health can have serious implications for the happiness and overall health of those who rely on their clinicians for care. Monday’s Daltroy Memorial Lecture sought to equip rheumatologists with the…
B cells have played a pivotal role throughout the history of lupus research. Shaun Jackson, MD, PhD, reviewed mechanistic insights from animal models, translational findings in human disease, and the implications for current and emerging therapies.
In Monday’s Great AI Debate, Jeffrey Curtis, MD, MS, MPH, presented the case that artificial intelligence (AI) augments clinicians in their care of patients, while Jinoos Yazdany, MD, MPH, cautioned that AI needs guardrails for use in healthcare.
Georg Schett, MD, summarized findings from multiple studies of the effects of chimeric antigen receptor T cell therapy in children aimed at inhibiting the progression of damage and organ failure and the cessation of chronic immunosuppression.
Peter Nigrovic, MD, reviewed new insights into the basic science of rheumatic disease in childhood, including groundbreaking work in juvenile idiopathic arthritis. Karen Onel, MD, discussed advances in clinical science.